ADCYAP1抗体;ADCYAP1 Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human cerebrum tissue lysate, Primary antibody: P12610(ADCYAP1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12610(ADCYAP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ADCYAP1 antibody is a crucial tool for studying the adenylate cyclase-activating polypeptide 1 (ADCYAP1), also known as pituitary adenylate cyclase-activating polypeptide (PACAP). Encoded by the ADCYAP1 gene, this neuropeptide plays diverse roles in stress response, circadian rhythm regulation, energy metabolism, and immune modulation. It binds to G protein-coupled receptors (PAC1. VPAC1. VPAC2), activating intracellular signaling pathways like cAMP/PKA and MAPK.

ADCYAP1 antibodies are designed to detect and quantify PACAP in various experimental applications, including Western blotting, immunohistochemistry (IHC), and ELISA. These antibodies, often raised in rabbits, mice, or goats, are available as polyclonal or monoclonal forms, with specificity validated via knockout controls or siRNA knockdown. Researchers use them to map PACAP distribution in tissues, particularly the central nervous system, endocrine organs, and gut, and to investigate its involvement in diseases such as neurodegenerative disorders (e.g., Alzheimer’s), metabolic syndromes, and cancer.

Recent studies highlight ADCYAP1's dual role in promoting tumor growth or apoptosis, depending on context, making its antibody valuable in oncology research. Additionally, it aids in exploring PACAP's therapeutic potential for stress-related psychiatric conditions or traumatic brain injury. Proper validation remains critical to ensure antibody reliability across species and experimental models.